secwatch / observer
8-K filed June 13, 2023, 7:59 PM ET ticker IMNM CIK 0001472012
other confidence high sentiment neutral materiality 0.15

Immunome shareholders reject officer exculpation amendment at annual meeting

Immunome Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunome Inc. shareholders rejected Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation at the 2023-06-07 meeting.

Proposal
charter amendment
Outcome
failed
Meeting
2023-06-07
Exact text from the filing
Proposal 2: Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation The amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was not approved by an affirmative vote of a majority of the shares of common stock outstanding and entitled to vote at the Annual Meeting, with the following votes tabulated: For Against Abstain Broker Non-Vote Total 3,528,592 86,542 4,771 4,115,553 7,735,458
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunome Inc. shareholders approved Election of Class III Directors for a Three-Year Term Expiring in 2026 at the 2023-06-07 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-07
Exact text from the filing
Proposal 1: Election of Class III Directors for a Three-Year Term Expiring in 2026 The following three nominees were elected to serve as Class III directors until the 2026 Annual Meeting of Stockholders of the Company and until their respective successors are elected and qualified, with the following votes tabulated: For Withheld Broker Non-Vote Total Richard A. Baron 2,897,767 722,138 4,115,553 7,735,458 Philip Wagenheim 3,287,880 332,025 4,115,553 7,735,458
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immunome Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023 at the 2023-06-07 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-07
Exact text from the filing
Proposal 3: Ratification of the Selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023 The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2023 was ratified, with the following votes tabulated: For Against Abstain Total 7,578,396 153,921 3,141 7,735,458
View on SEC.gov

289 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Immunome Inc. filing history →

Source: SEC EDGAR
accession 0001104659-23-070864
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.